STOCK TITAN

argenx SE - $ARGX STOCK NEWS

Welcome to our dedicated page for argenx SE news (Ticker: $ARGX), a resource for investors and traders seeking the latest updates and insights on argenx SE stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect argenx SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of argenx SE's position in the market.

Rhea-AI Summary
argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® (VYVGART) in neuromuscular autoimmune disease. The data presentations will be featured at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. Long-term clinical trial and real-world data show consistent and repeatable responses, achievement of minimal symptom expression, and favorable safety profile with VYVGART. Positive results from the ADHERE study of VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
-
Rhea-AI Summary
argenx SE announces $329 million in global net product sales for Q3 2023, plans to submit VYVGART Hytrulo sBLA for CIDP by year-end 2023, and publishes results from the ADVANCE-IV study. The company is focused on expanding VYVGART's reach and advancing its FcRn portfolio in autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
-
Rhea-AI Summary
argenx to host conference call and webcast to discuss Q3 2023 financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences earnings
Rhea-AI Summary
Health Canada authorizes VYVGART for the treatment of gMG in Canada
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
argenx receives positive CHMP opinion for SC injectable formulation of efgartigimod for the treatment of gMG
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary
argenx to participate in upcoming investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary
argenx SE announces its half-year 2023 financial results and second-quarter business update. VYVGART® global net product sales reached $269 million in Q2 2023. The company launched VYVGART Hytrulo in the U.S. and shipped the first vials in July. Topline results from ADVANCE-SC and ADDRESS studies expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
argenx, a global immunology company, will host a conference call on July 27, 2023, to discuss its half year 2023 financial results and provide a second quarter business update. The webcast can be accessed on the argenx website. Dial-in numbers are provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
argenx SE

Nasdaq:ARGX

ARGX Rankings

ARGX Stock Data

21.46B
58.81M
0%
55.84%
2.03%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Breda

About ARGX

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.